Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Jul 15, 2026; 18(7): 121250
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.121250
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.121250
Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium
Salih Karatlı, Doğan Yazılıtaş, Seher Kaya, Gökşen İ İmamoğlu, Selahattin Çelik, Galip C Uyar, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06000, Türkiye
Author contributions: Karatlı S and Yazılıtaş D designed the study; Karatlı S performed data collection and statistical analysis, wrote the original draft; Yazılıtaş D supervised the study; Kaya S, İmamoğlu Gİ, Çelik S and Uyar GC contributed to data interpretation and manuscript revision; and all authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Ankara Etlik City Hospital Scientific Research Ethics Committee (Decision No: AEŞH-BADEK2-2025-438, date: September 16, 2025).
Informed consent statement: Informed consent was waived due to the retrospective design and use of anonymized data.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-a checklist of items.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Salih Karatlı, MD, Department of Medical Oncology, Ankara Etlik City Hospital, Varlık Neighborhood, Halil Sezai Erkut Avenue, Yenimahalle, Ankara 06000, Türkiye. karatlisalih@hotmail.com
Received: March 19, 2026
Revised: April 8, 2026
Accepted: April 22, 2026
Published online: July 15, 2026
Processing time: 110 Days and 16.4 Hours
Revised: April 8, 2026
Accepted: April 22, 2026
Published online: July 15, 2026
Processing time: 110 Days and 16.4 Hours
Core Tip
Core Tip: Pan-immune-inflammation value (PIV) is a novel biomarker reflecting systemic inflammatory and immune status in hepatocellular carcinoma (HCC). In this retrospective study, PIV demonstrated superior prognostic performance compared with conventional liver function scores such as albumin-bilirubin and model for end-stage liver disease-sodium and remained an independent predictor of overall survival. These findings suggest that inflammation-based indices may improve risk stratification beyond traditional liver function-based models in patients with HCC.